Xenetic Biosciences (NASDAQ: XBIO) is a clinical-stage biopharmaceutical company that focuses on the discovery, development and planned commercialization of human drug therapies for the treatment of various conditions. Its drug delivery platform systems include PolyXen for creating next generation biologic drugs; OncoHist for the development of oncology drugs focused on orphan indications; Virexxa for the treatment of progesterone receptor negative endometrial cancer; and ImuXen for the development of vaccines that can simultaneously deliver multiple active pharmaceutical ingredients. Its product candidates comprise ErepoXen, a polysialylated erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease; and OncoHist, an orphan drug that is in pre-clinical stage of development for the treatment of refractory acute myeloid leukemia. The company is also developing a pipeline of drug candidates for next generation biologics and novel oncology therapeutics in various orphan disease indications. For more information, visit the company’s website at www.xeneticbio.com.
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
